CALIDAD DE VIDA RELACIONADA A LA SALUD Y COSTOS DEL SISTEMA DE SALUD, POR PÉRDIDA DE PRODUCTIVIDAD Y OTROS DE PACIENTES CON DIAGNOSTICO DE CÁNCER DE MAMA EN AMÉRICA LATINA Y EL CARIBE: REVISIÓN SISTEMÁTICA Y META-ANALISIS

AUGUSTOVSKI F; PECKAITIS, CLAUDIA; ARIEL BARDACH; LUCAS GONZALEZ; AGUSTÍN CIAPPONI; ALFREDO PALACIOS; ANDRÉS PICHON-RIVIERE

Congreso; ISPOR 2019 COLOMBIA; 2019

OBJECTIVES: Breast cancer (BC) is the most common cancer in women. Our study reviewed available data in Latin America and the Caribbean (LAC) that characterize health related quality of life (HRQoL) of patients with BC and related costs, including healthcare costs, patient and family costs (e.g productivity loss).METHODS: Systematic literature review was conducted to identify relevant published articles in PubMed, LILACS, Trip, Embase, the CEA registry, CRD, EconLit, PsycINFO and grey literature published between 2008 and August 2018. At least two independent reviewers screened, extracted data and assessed the methodological quality of each of included studies. For HRQoL we pooled the results from individual studies using the random‐effects model of meta‐analysis and conducted subgroup analyses by country, disease stage and instrument used.RESULTS: From 2265 initial references, 125 articles were finally included (52% from Brazil; 21% from Mexico; 10% from Colombia; 5% from Argentine; and 12% from others). Seventy-five (n=8806) assessed HRQoL. The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 and B23 module (34 studies; 8 countries; n=4866) were the most used instruments, followed by SF-36 (19 studies; 6 countries; n= 1675), WHOQOL-BREF (14 studies; 2 countries; n=1459), FACT-B (11 studies; 4 countries; n=1057). Only 4 studies (4 countries; n= 315) reported disaggregated data of patients with metastatic disease. Forty-seven studies reported economic costs (24 cost estimation studies, 21 economic evaluations; 2 ?other?). Forty-two studies informed direct medical costs (10 countries) and only seven studies reported patient costs (4 countries). Meta-analytic analyses are not presented here due to space restrictions.CONCLUSIONS: This study provides an exhaustive analysis and synthesis of a heterogeneous body of evidence of breast cancer HRQoL and costs in LAC; and can provide reference values for this population in our region. It also signals important evidence gaps.